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Background: Appendiceal peritoneal carcinomatosis (PC) is rare and its long-term prognosis is poor. The aim of this
study was to evaluate the results of an aggressive treatment approach used in our institution for the last eight years.
Methods: Data from all patients with PC arising from the appendix were prospectively collected and analyzed. Treatment
consisted of complete surgical cytoreduction (CRS), followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with
oxaliplatin (460 mg/m2) at 43°C over 30 minutes. Ronnett’s histologic classification was used for tumor grading.
Results: Between February 2003 and April 2011, 78 patients underwent laparotomy with curative intent. The
mean follow-up period was 33.7 months. A total of 58 patients received HIPEC, but 11 patients could not have
CRS and received no HIPEC. Nine patients with a negative second-look surgery also received no HIPEC. The five-year
overall survival for the entire cohort was 66.2%; 100% for the negative second-look patients, 77% for the HIPEC patients
and 9% for the unresectable patients (P <0.0001). A total of 15 patients (25.9%) had isolated peritoneal recurrence, no
patient had visceral recurrence only, and five patients (8.6%) had both. In regards to the five-year disease-free survival
for the HIPEC patients, histologic grade (disseminated peritoneal adenomucinosis 100%, peritoneal mucinous
carcinomatosis with intermediate features 40%, peritoneal mucinous carcinomatosis 20%; p =0.0016) and completeness
of cytoreduction (CCR-0 56%, CCR-1 24%; P =0.0172) were prognostic factors. There was one postoperative mortality.
The major complication rate for patients treated with HIPEC was 40%, including intra-abdominal abcess (17%),
hemorrhage (12%) and anastomotic leak (10%). One patient in the HIPEC group experienced temporary grade II
neuropathy and grade III thrombocytopenia.
Conclusions: This therapeutic approach seems both feasible and safe in selected patients. Recurrence is, however,
frequent and represents a challenge.
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Neoplasms of the appendix are rare, with their age-
adjusted incidence rate being 0.12 to 2 cases per 1,000,000
people per year [1]. They are found in about 1% of ap-
pendectomy specimens [2]. Epithelial tumors, which rep-
resent the majority of the appendiceal cancers [1], often
present with peritoneal dissemination.
For those cases, the traditional approach has consisted
in repetitive debulking surgery and the long-term progno-
sis (five and ten-year overall survival (OS)) of these patients
has been demonstrated in two studies as being 53% and
32% [3], and 65% and 21% [4], respectively. A more aggres-
sive approach consisting of complete surgical cytoreduc-
tion (CRS) and intra-peritoneal chemotherapy has been
introduced by Gonzalez-Moreno and Sugarbaker in 1983,
with five- and ten-year OS rates of 71.9% and 54.5%, re-
spectively [5]. There are many studies published in the last
decade similarly showing improvement in long-term sur-
vival when compared to traditional debulking surgeries, with
five- and ten-year OS ranging from 40 to 87% and 50 to
74%, respectively [6-15]. The addition of hyperthermia to
chemotherapeutic agents has been shown to enhance their
cytotoxicity [16] and their penetration into tumors [16-18].
There is great variability in regards to the agent used for
the intraperitoneal chemotherapy protocol. Some investiga-
tors use mitomycin-C or 5-fluorouracil, whereas Elias et al.
have introduced oxaliplatin as a hyperthermic intraperito-
neal chemotherapy (HIPEC) agent for peritoneal carcin-
omatosis (PC) arising from the appendix [19]. In a phase
one study, intraperitoneal oxaliplatin had an advantageous
pharmacokinetic profile, displaying very high intraperito-
neal concentrations but low systemic toxicity because of
limited systemic absorption [20]. Its advantages also include
a reduced duration of perfusion, from 90 minutes for
mitomycin-C to 30 minutes, as well as a potentialization of
peritoneal concentration, while reducing systemic (plasmatic
of portal) concentrations in the context of HIPEC, as shown
through animal studies performed in our center [18].
The aim of this study was to analyze overall surgical out-
come, long-term survival, as well as to identify factors of
prognostic value for the patients treated in our institution
over the last eight years. It is an update on our series pub-
lished in 2008 and remains the first to use oxaliplatin ex-




From a prospective database, we included all patients
(n =78) with peritoneal surface dissemination of epithelial
appendiceal tumors treated in our center between February
2003 and February 2011. Our institution’s clinical trial re-
view board approved this study. Hôpital Maisonneuve-
Rosemont, University of Montreal. Patients are agreeing tobe part of the database when consenting to care. The fol-
lowing factors were analyzed: demographic data, surgical
procedures, pathologic diagnosis, complications and length
of hospital stay.
Patients were offered treatment consisting of maximal
surgical cytoreduction and HIPEC with oxaliplatin if they
fulfilled the following criteria: diagnosis proven by histo-
logical examination, no evidence of visceral metastasis on
computed tomographic (CT) imaging of the chest and ab-
domen, a technically resectable disease, and a general
health status good enough to tolerate the proposed surgery.
Surgery for peritoneal carcinomatosis and hyperthermic
intraperitoneal chemotherapy
The surgical technique for both PC and open-abdomen
HIPEC with oxaliplatin (460 mg/m2 at 42 to 44°C for
30 minutes) has been previously described [21].
Postoperative course
Patients were followed up on every day following surgery.
Surgical complications were graded using a five-point scale
[22]. Minor complications (grade I or II) that were man-
aged with pharmacological treatment (for example urinary
tract infection treated with antibiotics) or non-invasive
procedures (for example nasogastric tube for postoper-
ative ileus) were not considered. Major complications were
defined as grade III to V. A grade III complication is one
requiring surgical, endoscopic or radiological intervention
(such as an intra-abdominal abscess). A grade IV com-
plication is considered life-threatening and requires
ICU management (such as hemorrhagic shock). Grade
V is defined as postoperative mortality. We included all
complications directly related to the surgical procedure,
even if they occurred beyond 30 days postoperatively.
Chemotherapy-associated complications were graded ac-
cording to the Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0.
Pathology
Pathologic classification was performed by an experienced
pathologist in our hospital. When surgery of the primary
tumor had not been performed in our institution, the path-
ology material was reviewed by the same pathologist to
provide uniform application of diagnostic and grading cri-
teria. Tumor grading of both primary (when available) and
peritoneal deposits was done according to Ronnett’s histo-
logic classification [23]. Disseminated peritoneal adenomu-
cinosis (DPAM) was characterized histologically by the
presence of scant low-grade adenomatous mucinous epi-
thelium within abundant extracellular mucin and associ-
ated fibrosis. Peritoneal mucinous carcinomatosis (PMCA)
displayed the cytologic and architectural features of higher-
grade mucinous carcinoma associated with extracellu-
lar mucin, often with invasive components and sometimes
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eal mucinous carcinomatosis with intermediate features
(PMCA-I) presented with combined DPAM and PMCA
characteristics; such tumors were invariably derived from
well-differentiated mucinous adenocarcinomas of the
appendix.
Systemic chemotherapy
Perioperative systemic chemotherapy was administered
to all PMCA patients. Systemic chemotherapy was also
administered preoperatively for three to six months to
patients with lower grade disease with extensive disease,
defined as an estimated Peritoneal Cancer Index (PCI)
[24] greater than 25. This systemic treatment was aimed
at diminishing the tumor burden in order to maximize
the chance of complete surgical cytoreduction thereafter.
Chemotherapy consisted of 5-fluorouracil with irinotecan
or oxaliplatin.
Follow-up
Patients were seen at an outpatient clinic at four-month
intervals, at which a physical examination was performed.
A CT scan of the abdomen and pelvis was performed every
four months for two years, every six months for an add-
itional three years and yearly thereafter.
Statistics
Data were obtained from a prospective database of clinical
records as well as surgical, pathological and radiological
reports. No patients were lost during the follow-up period.
Kaplan-Meier’s survival curves were established and were
compared with log-rank tests. The Cox proportional-
hazards regression model was used to analyze the influence
of different factors on disease-free survival (DFS) and OS.
Differences were considered significant at P ≤0.05. Data
were analyzed using Prism (GraphPad Software, San Diego,
California, United States) and JMP™ 6.0 (SAS Institute Inc.
Cary, North Carolina, United States).
Results
Between February 2003 and February 2011, 78 patients
with a PC originating from the appendix underwent lapar-
otomy with curative intent. There were 34 males and 44 fe-
males, with a mean age of 50 (range 32 to 70) years. The
primary tumor had been removed in 72 patients. At lapar-
otomy, 14 patients were found to have unresectable disease,
either because of too extensive PC or intraoperative discov-
ery of visceral metastasis. Of note, two of these patients
underwent repeat surgery with successful cytoreduction
and HIPEC after six months of systemic chemotherapy.
Nine other patients initially diagnosed with a mucinous
tumor of the appendix with limited peritoneal disease had
no evidence of PC when a second-look laparotomy was
performed in our center six to twelve months later. Allthese patients had undergone appendectomy along with
the complete removal of peritoneal tumor in another
center before being referred to us. Four of these nine
patients with well-differentiated cystadenocarcinoma of
the appendix underwent complementary right hemico-
lectomy at second-look surgery for staging purposes. Since
these patients had no evidence of residual disease they were
not treated with HIPEC.
Complete surgical cytoreduction followed by HIPEC was
performed in 58 patients. The CCR Completeness of
Cytoreduction score [25] was 0 for 43 patients and one
for 15 patients. In the HIPEC group, the median periton-
eal cancer index was 13 (2 to 28), patients had a mean of
1.4 (0 to 5) organs resected and 0.6 (0 to 2) anastomosis.
Median operative time was 362 (135 to 855) minutes and
the median blood loss was 600 (50 to 7300) ml. The me-
dian length of hospital stay for HIPEC patients was 16 (7
to 104) days. One patient died 16 days following surgery
and HIPEC. He presented with sepsis and multi-organ
failure. The overall major (grade III to V) complication rate
was of 39% (23 out of 58), including intra-abdominal ab-
scesses (22%, 13 out of 58), hemorrhage (17%, 10 out of 58)
and anastomotic leaks (10% of patients, six out of 58; 17%
of anastomoses, six out of 35). One patient in the HIPEC
group experienced grade II neuropathy that lasted for one
week following surgery. The same patient also developed
grade III thrombocytopenia one week postoperatively.
Final pathology reports showed disseminated peritoneal
adenomucinosis (DPAM) in 19 patients (24%, 19 out of 78)
(HIPEC n =14, negative second-look (on initial pathology)
n =5, unresectable n =0), PMCA-I in 41 patients (53%, 41
out of 78) (HIPEC n =34, negative second-look (on initial
pathology) n =3, unresectable n =4) and PMCA in 18 pa-
tients (23%, 18 out of 78) (HIPEC n =10, negative second-
look (on initial pathology) n =1, unresectable n =7).Survival rates
The mean follow-up period was 33.7 months (median:
29.1; range: 2 to 100.8) for the entire series. The estimated
five-year OS rate for the entire series was 66% (95% CI, 51
to 78). The estimated five-year OS was 100% for the nega-
tive second-look patients, 77% (95% CI, 57 to 88) for the
HIPEC patients, and 9% (95% CI, 1 to 33) for the unre-
sectable patients (P <0.0001) (Figure 1). In the HIPEC
group, at the time of data analysis, 15 patients (25.9%) had
isolated peritoneal recurrence, no patient had visceral re-
currence only, and five patients (8.6%) had both. The esti-
mated five-year DFS for the HIPEC group was 50% (95%
CI, 30 to 66) and 100% for the negative second-look group
(P =0.0478) (Figure 2).
On univariate analysis, histologic grade was an import-
ant prognostic indicator of both five-year DFS for HIPEC
patients (P =0.0016) and five-year OS for the entire cohort
Figure 3 Overall survival of entire series at 60 months according
to histologic grade. Histologic types: disseminated peritoneal
adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA)
and peritoneal mucinous carcinomatosis with intermediate features
(PMCA-I).
Figure 1 Overall survival at 60 months for patients who
underwent complete surgical cytoreduction followed by
hyperthermic intraperitoneal chemotherapy (HIPEC) who
were found to have unresectable disease and those who had
a negative second-look surgery.
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OS was 100% and 100% for DPAM, 40% (95% CI, 17 to 62)
and 40% (95% CI, 17 to 62) for PMCA-I, as well as 20%
(95% CI, 1 to 55) and 20% (95% CI, 1 to 55) for PMCA. OS
curves were statistically different between the PMCA-I
and PMCA groups (P <0.0003), between the DPAM
and the PMCA groups (P <0.0003) but they were not
statistically significantly different between the DPAM and
the PMCA-I groups. The cytoreduction score was also a
significant prognostic factor of five-year DFS (P =0.0172)
with survival of 56% (95% CI, 32 to 74) for CCR-0 and
24% (95% CI, 2 to 61) for CCR-1, but a significant differ-
ence in OS was not found between the two groups, with a
survival of 81% (95% CI, 56 to 93) for CCR-0 and 64%
(95% CI, 32 to 85) for CCR-1. Other parameters such
as age, sex, peritoneal index, duration of surgery, blood
loss, systemic chemotherapy (neoadjuvant or adjuvant)
and the occurrence of major complications had no sig-
nificant influence on survival at univariate analysis.
Finally, the nine patients who underwent second-look
laparotomy and were found to have no disease were also
followed and are still disease-free.Figure 2 Disease-free survival at 60 months for patients who
underwent hyperthermic intraperitoneal chemotherapy (HIPEC)
and those who had a negative second-look surgery.Discussion
PC arising from the appendix is a rare condition with a
poor long-term prognosis. An aggressive surgical approach
seems to be warranted and many centers have recently
published their results. There seems to be a survival benefit
of CRS and HIPEC administration compared to surgical
debulking alone. For example, Gonzalez-Moreno and
Sugarbaker (n =501), Elias et al. (n =301), Youssef et al.
(n =289) and Baratti et al. (n =104) reported the largest
series of patients treated by CRS and HIPEC, with five-
year OS rates of 71.9%, 73%, 87% and 71.9% respectively
[5,10-12] (Table 1). These results compare favorably to the
five-year OS rate of 53% by Gough et al. and 65% by
Miner et al., who treated their patients with surgical
debulking alone [3,4].
Although effective, CRS is a lengthy procedure, with
extensive dissection and numerous organ resections in
order to achieve maximal cytoreduction (CCR-0 or CCR-
1) to allow for the administration of HIPEC. As already
published, it was found that completeness of cytoreduc-
tion was a prognostic factor for DFS [5,6,15]. Although
oxaliplatin has been demonstrated to penetrate the peri-
toneal tissues to a depth of up to 2.5 mm [17,25], it seems
that CRS has a superior impact on prognosis than chemo-
therapy itself. Therefore, one should attempt maximal
efforts to achieve complete macroscopic cytoreduction.
However, the capacity to achieve CRS is dependent on
the extent of peritoneal disease (PCI score) and grade
of tumor [8,13,14]. In our series, a CCR-0 resection was
achieved in 43 of the 68 patients (63%), consistent with
other teams [6,8,10,11,15]. Median PCI, at 13, is somewhat
lower than what was reported by other groups, raising
some questioning regarding variability in PCI assessment
among different teams.
In regards to tumor grading, there has been recent debate
about Ronnett’s original classification into three categories
[26]. Indeed, many teams have lately been classifying
PC arising from the appendix in two categories (low- versus
Table 1 Effectiveness of perioperative intraperitoneal chemotherapy (PIC) for peritoneal carcinomatosis arising from






Overall survival (%) Disease-free survival (%)
1 year 3 years 5 years 10 years 1 year 3 years 5 years
Sugarbaker [5] HIPEC or EPIC (MMC) 501 48 --- --- 71.9 54.5 --- --- ---
Elias [11] HIPEC (OX or MMC) 301 88 --- --- 73 --- --- --- 56
Moran [12] HIPEC (MMC) 289 39 --- --- 87 74 --- --- 70
Choudry [15] HIPEC (MMC) 282 24 --- 67.4 52.7 --- --- 45.1 32.1
Morris [6] HIPEC (MMC) 106 23 --- --- 75 --- 71 51 38
Deraco [10] HIPEC (MMC) 104 37 --- --- 71.9 --- --- --- 38.8
Zoetmulder [8] HIPEC (MMC) 103 51.5 90 70.9 59.5 >50 --- 43.6 37.4
Sardi (PMCA) [14] HIPEC (MMC) 77 18 88 56 40 --- --- --- ---
Temple [13] HIPEC (MMC) 58 28 --- 76 62 --- --- 48 42
Current study HIPEC (OX) 58 29.1 --- --- 66.2 --- --- --- 50
EPIC, early postoperative intraperitoneal chemotherapy; HIPEC, Hyperthermic intraperitoneal chemotherapy; MMC, mitomycin C; OX, oxaliplatin.
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because of findings of comparable survival [15,27]. Our
findings that the OS of PMCA-I patients is closer to DPAM
than PMCA on univariate analysis support that classifica-
tion. Others proposed that CP arising from non-mucinous
adenocarcinoma (classic type) be regarded as a separate
category because they lead to the poorest outcome [28].
Although a binary classification seems to be simpler and
more reproducible, until a consensus is established, we have
chosen to use the original Ronnett’s classification, in order
to compare with other groups and to allow for continuity
with the preliminary results we published in 2008 [21].
CRS plus HIPEC remains a procedure with a high
rate of major complications (Table 2) [6,8,10-12,14,15,29].
However, it is noteworthy that the frequency of systemic
(hematologic) toxicity was low, confirming the reports of
Elias et al. [20]. The fact that chemoperfusion takes 60 mi-
nutes less to perform than for the mitomycin-C is another
reason why we prefer to use oxaliplatin for HIPEC.
A total of 15 patients (26%) in the HIPEC group pre-
sented an isolated peritoneal recurrence, a median ofTable 2 Morbidity and mortality of cytoreductive surgery com
(PIC) in peritoneal carcinomatosis arising from the appendix
Chief-Investigator Center n Mor
Elias [11] Multicentric 301
Morran [12] Basingstoke, UK 289
Choudry [15] Pittsburgh 282
Sugarbaker [29] Washington, DC 155
Sardi [14] Baltimore 77
Morris [6] Sydney 106
Deraco [10] Milan 104
Zoetmulder [8] Amsterdam 103
Current study Montreal 5818 months after the HIPEC procedure. Five of them were
eligible for repeat surgery and accepted to undergo an-
other CRS with HIPEC procedure using mitomycin-C.
It is important to mention that one patient with PMCA
disease in the negative second-look surgery in our prelim-
inary series finally received CRS and HIPEC after present-
ing a peritoneal recurrence 36 months after a negative
exploration. He presented with another peritoneal recur-
rence a year after the HIPEC with oxaliplatin. He then
underwent another CRS and HIPEC with mitomycin-C
but succumbed to the disease 16 months later. With a me-
dian follow-up period of more than two years, the OS and
DFS survival for the remaining nine negative second-look
patients are both 100%, which gives us cause to believe
that a prophylactic HIPEC may not be warranted for
patients with low-grade disease.
Elias et al. recently published the results of their retro-
spective trial of prophylactic HIPEC for asymptomatic
patients at high risk of presenting colorectal PC (resected
synchronous macroscopic PC, ovarian metastasis or tumor
perforation) [30]. Peritoneal disease was found in morebined with perioperative intraperitoneal chemotherapy
(pseudomyxoma peritonei)
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(including those without macroscopic evidence of periton-
eal disease recurrence) underwent HIPEC with oxaliplatin.
OS at five years is encouraging, at 90%. We believe that
patients with appendiceal carcinomatosis with high-grade
disease (PMCA, classic adenocarcinoma or signet-ring cell
lesions) would benefit from a similar approach and receive
prophylactic HIPEC.
Concerning patients with unresectable disease, they had
a more aggressive disease (64% PMCA and 36% PMCA-I)
and 10 out of the 11 patients died a median of 11.2 months
after surgery. In a study of 18 patients with peritoneal car-
cinomatosis arising from an appendiceal adenocarcinoma
with signet-ring cells, 10 patients were able to get CRS
and HIPEC, whereas eight patients were only adminis-
tered intravenous chemotherapy because of failure to get
complete CRS. Median survival was found to be 27 versus
15 months, respectively [31]. Although not statistically sig-
nificant (P =0.12), it seems that the longer survival supports
aggressive surgical management, while being reasonable in
order to prevent unwarranted complications. In our series,
two patients with bulky disease (PMCA-I) that was deemed
unresectable at first laparotomy received intravenous
systemic chemotherapy (FOLFOX) followed by abdominal
reexploration six months later. They then underwent a
CCR-0 cytoreduction and HIPEC. With a follow-up period
of 42 and 45 months respectively, they are both alive with-
out evidence of disease.Conclusions
This therapeutic approach seems both feasible and safe in
selected patients. Survival and morbidity with oxaliplatin
is similar to what has been reported for HIPEC with
mitomycin-C. The major complication rates of these pro-
cedures remain high and constant efforts to reduce the
operative morbidity is warranted. Recurrence is, however,
frequent and represents a challenge. Chemotherapy is
warranted for patients with PC deemed unresectable upon
initial exploration and a second-look should be performed
since chemotherapy can reduce tumor burden enough to
allow for complete cytoreduction and HIPEC.Abbreviations
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